Targeting Brn-3b in breast cancer therapy.
The Brn-3b POU domain transcription factor is elevated in a significant proportion of breast cancers and in neuroblastoma tumours, where it is associated with increased proliferation, anchorage-independent growth, faster and larger tumour growth in xenograft models, resistance to growth inhibitory stimuli and increased migratory potential. These effects are associated with the ability of Brn-3b to regulate specific genes associated with these processes. Reducing Brn-3b can reverse many of these effects, suggesting that it may be possible to alter the growth and behaviour of tumour cells by abrogating Brn-3b in these cancers. This review discusses the effect of altering Brn-3b in these cancer cells and possible approaches to targeting Brn-3b as a strategy for therapy in treatment of breast cancers.
Budhram-Mahadeo
Vishwanie S
VS
Medical Molecular Biology Unit, Institute of Child Health, University College London, London WC1N 1EH, UK. v.mahadeo@ich.ucl.ac.uk
Latchman
David S
DS
D000595:Amino Acid Sequence; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008969:Molecular Sequence Data; D050820:Transcription Factor Brn-3B / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; C494190:POU4F2 protein, human; D050820:Transcription Factor Brn-3B